Cellectis reports financial results for first quarter 2026
Biotech firm Cellectis reported $188 million in cash reserves as of March 31, 2026, alongside updates on its clinical trial milestones.
Cellectis released its financial results for the first quarter of 2026, reporting cash, cash equivalents, and fixed-term deposits of $188 million. The company stated this capital provides sufficient liquidity to fund operations into the fourth quarter of 2027.
The company is advancing several clinical programs, with an interim analysis of the phase 2 pivotal trial for lasme-cel in B-cell acute lymphoblastic leukemia expected in the fourth quarter of 2026. Cellectis projects a potential filing for regulatory approval in 2028. Meanwhile, full data from the phase 1 study for eti-cel is also slated for release in the fourth quarter of 2026.
CEO André Choulika noted that interim data regarding the cema-cel program, published by partner Allogene, supports the company's objective to expand access to off-the-shelf cell therapies. Beyond its current clinical pipeline, Cellectis is preparing to present new preclinical findings regarding epigenetic editing at the upcoming ASGCT event.